Current options for patients with MM consist of a multimodal regimen of chemotherapy, using platinum-based compounds and folate antagonists, combined with anti-vascular endothelial growth factor (VEGF) antibody bevacizumab, surgery and radiotherapy. Here, VEGFA is linked to Miyoshi myopathy.